The American Society of Gene & Cell Therapy (ASGCT) and Orphan Therapeutics Accelerator (OTXL), a biotech non-profit, have launched the CGTxchange, a jointly owned clearinghouse and marketplace designed to identify, evaluate and advance clinically validated cell and gene therapies (CGTs) for ultra-rare diseases that have been shelved due to commercial constraints. This will serve as…